Information Provided By: 
Fly News Breaks for August 14, 2018
PFE
Aug 14, 2018 | 07:13 EDT
Cantor Fitzgerald analyst Louise Chen thinks the peak sales potential of one of Pfizer's Xeljanz is being underappreciated by investors. Xeljanz is increasingly becoming a go-to product for rheumatologists and gastroenterologists because of its broad array of indications, ease-of-use and good tolerability profile, Chen tells investors in a research note. She expects the combination of the new indications to add $1B-plus of sales to Xeljanz. The analyst reiterates an Overweight rating on Pfizer with a $45 price target.
News For PFE From the Last 2 Days
PFE
Apr 22, 2024 | 08:13 EDT
Pfizer announced that the European Commission, or EC, has granted marketing authorization for Emblaveo for the treatment of adult patients with complicated intra-abdominal infections, or cIAI, hospital-acquired pneumonia, or HAP, including ventilator-associated pneumonia, or VAP, and complicated urinary tract infections, or cUTI, including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
